Triclabendazole to treat fascioliasisApril 9, 2019
Novartis said triclabendazole (Egaten) has won approval from the US FDA for the treatment of fascioliasis in patients six years of age and older.
Triclabendazole is currently the only medicine for fascioliasis recommended by the WHO and is on the WHO Model List of Essential Medicines.
Fascioliasis, commonly known as liver fluke infestation, is a neglected tropical disease that infects 2.4 million people worldwide, with an additional 180 million at risk of infection. It is caused by two species of parasitic flatworms or trematodes that mainly affect the liver (Fasciola hepatica or Fasciola gigantica). Both species can infect humans following ingestion of larvae in contaminated water or food (mainly raw or undercooked vegetation). The larvae mature into adult worms in the biliary tract. No continent is free from fascioliasis; human cases have been reported from more than 70 countries worldwide.